• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    3/20/24 1:31:24 PM ET
    $ANVS
    $APM
    $BCLI
    $ETAO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANVS alert in real time by email

    Gainers

    • XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 95.8% to $2.04 during Wednesday's regular session. The company's market cap stands at $11.0 million.
    • Etao International Co (NASDAQ:ETAO) stock rose 84.65% to $0.26. The company's market cap stands at $26.6 million.
    • Annovis Bio (NYSE:ANVS) shares moved upwards by 39.12% to $12.41. The company's market cap stands at $131.2 million.
    • Brainstorm Cell (NASDAQ:BCLI) stock increased by 33.28% to $0.47. The market value of their outstanding shares is at $23.2 million.
    • SCWorx (NASDAQ:WORX) stock moved upwards by 26.23% to $3.58. The company's market cap stands at $4.3 million.
    • Taysha Gene Therapies (NASDAQ:TSHA) shares increased by 24.88% to $2.81. The market value of their outstanding shares is at $525.3 million. As per the news, the Q4 earnings report came out yesterday.

    Losers

    • Lifecore Biomedical (NASDAQ:LFCR) stock declined by 31.4% to $4.93 during Wednesday's regular session. The company's market cap stands at $145.4 million.
    • Ontrak (NASDAQ:OTRK) shares fell 29.29% to $0.31. The market value of their outstanding shares is at $8.5 million.
    • Longeveron (NASDAQ:LGVN) stock fell 20.31% to $0.36. The market value of their outstanding shares is at $9.0 million.
    • Fresh2 Group (NASDAQ:FRES) stock decreased by 19.45% to $0.45. The market value of their outstanding shares is at $10.6 million.
    • Aptorum Gr (NASDAQ:APM) shares fell 18.07% to $7.89. The market value of their outstanding shares is at $40.8 million.
    • Seelos Therapeutics (NASDAQ:SEEL) stock decreased by 16.93% to $0.54. The market value of their outstanding shares is at $7.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ANVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANVS
    $APM
    $BCLI
    $ETAO

    CompanyDatePrice TargetRatingAnalyst
    Lifecore Biomedical Inc.
    $LFCR
    3/17/2026$5.50Mkt Perform → Outperform
    Barrington Research
    Taysha Gene Therapies Inc.
    $TSHA
    10/21/2025$13.00Strong Buy
    Raymond James
    Lifecore Biomedical Inc.
    $LFCR
    9/4/2025Sector Weight
    KeyBanc Capital Markets
    Taysha Gene Therapies Inc.
    $TSHA
    7/11/2025$8.00Buy
    BofA Securities
    Lifecore Biomedical Inc.
    $LFCR
    5/21/2025Outperform
    William Blair
    Annovis Bio Inc.
    $ANVS
    2/10/2025Buy → Hold
    D. Boral Capital
    Longeveron Inc.
    $LGVN
    12/6/2024$10.00Buy
    ROTH MKM
    Annovis Bio Inc.
    $ANVS
    10/25/2024$25.00Hold → Buy
    Maxim Group
    More analyst ratings

    $ANVS
    $APM
    $BCLI
    $ETAO
    SEC Filings

    View All

    SEC Form 10-K filed by Brainstorm Cell Therapeutics Inc.

    10-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    3/31/26 5:26:31 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Aptorum Group Limited

    6-K - Aptorum Group Ltd (0001734005) (Filer)

    3/31/26 4:54:54 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    3/31/26 4:16:24 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANVS
    $APM
    $BCLI
    $ETAO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Segal Niv

    3 - XTL BIOPHARMACEUTICALS LTD (0001023549) (Issuer)

    3/23/26 4:01:12 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Hillel Fain Osnat

    3 - XTL BIOPHARMACEUTICALS LTD (0001023549) (Issuer)

    3/23/26 4:01:14 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Willard Stephen H was granted 400,000 shares and covered exercise/tax liability with 105,533 shares (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    3/13/26 8:59:13 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    $APM
    $BCLI
    $ETAO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update

    Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidenceCompany highlights durable long-term survival in Expanded Access Program (EAP) cohort supporting Phase 3b patient selection and inclusion criteriaNEW YORK, March 31, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2025, and provided a corporate update. "Our main priority continues to be advancing NurOwn

    3/31/26 4:01:00 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Annovis Publishes Historical Review of Buntanetap in The Scientist

    MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the publication of an article in The Scientist titled "Buntanetap: From Execution Poison to Potential Alzheimer's Disease Drug", examining the history of discovery and development of buntanetap, the Company's lead drug candidate. As Annovis advances its clinical pipeline with both AD and PD trials actively enrolling patients, this historical review offers important contex

    3/31/26 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore") a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that effective on March 25, 2026, Lifecore granted a restricted stock unit ("RSU") award with respect to 18,500 shares of its common stock under Lifecore's Equity Inducement Plan, as amended (the "Inducement Plan") to a newly hired employee of Lifecore. The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by Lifecore's compensation committee and was grante

    3/26/26 4:05:00 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    $APM
    $BCLI
    $ETAO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hoffman Michael B bought $193,794 worth of shares (45,000 units at $4.31), increasing direct ownership by 2% to 2,574,739 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    12/8/25 8:05:14 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Hoffman Michael B bought $159,886 worth of shares (39,200 units at $4.08), increasing direct ownership by 2% to 2,529,739 units (SEC Form 4)

    4/A - Annovis Bio, Inc. (0001477845) (Issuer)

    11/25/25 6:59:54 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoffman Michael B bought $159,886 worth of shares (39,200 units at $4.08), increasing direct ownership by 2% to 2,519,739 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    11/25/25 12:26:46 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    $APM
    $BCLI
    $ETAO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lifecore Biomedical upgraded by Barrington Research with a new price target

    Barrington Research upgraded Lifecore Biomedical from Mkt Perform to Outperform and set a new price target of $5.50

    3/17/26 7:45:07 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Taysha Gene Therapies with a new price target

    Raymond James initiated coverage of Taysha Gene Therapies with a rating of Strong Buy and set a new price target of $13.00

    10/21/25 7:22:35 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    KeyBanc Capital Markets initiated coverage on Lifecore Biomedical

    KeyBanc Capital Markets initiated coverage of Lifecore Biomedical with a rating of Sector Weight

    9/4/25 9:01:33 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    $APM
    $BCLI
    $ETAO
    Leadership Updates

    Live Leadership Updates

    View All

    XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

    RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari

    2/27/26 4:30:00 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

    MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results. "The past quarter delivered breakthrough progress on every front," said Maria Maccecchini, Ph.D., President and CEO of Annovis. "Our pivotal Phase 3 Alzheimer's study has achieved full activation across all clinical sites, with enrollment momentum advancing every day. We have fortified our intellectual property position by transferring al

    11/12/25 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    $APM
    $BCLI
    $ETAO
    Financials

    Live finance-specific insights

    View All

    Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

    Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to <4 years with inclusion of ≥3 months of safety data in planned BLA submission to support potential for broad label; on track to complete dosing in Q2 2026 Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEAL Phase 1/2 and REVEAL pivotal trials as of March 2026 data cutoff; longer-term safety and efficacy data from Part A of REVEAL Phase 1/2 trials expected in Q2 2026 Reached written alignment with FDA on proposed PPQ

    3/19/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update

    -- Recorded Fourth Quarter Revenues of $35.7 Million and Transition Period Revenues of $75.5 Million -- -- Multiple New Programs Signed in Fourth Quarter 2025 Including Two Commercial Site Transfer Programs, for Total of Five New Programs in 2025 Transition Period -- -- Organizational Initiatives Drive Further Improvement in Margins -- Conference Call Today at 8:30am ET CHASKA, Minn., March 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced strong results for the fourth quarter and transition period ended December 31, 2025

    3/16/26 8:00:00 AM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANVS
    $APM
    $BCLI
    $ETAO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary